Finally, we find that that there are marked sex-specific differences for particular treatments, namely epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer (NSCLC) and rituximab in non-Hodgkin’s lymphoma (NHL), that extend beyond the overall underlying sex differences in survival in these two malignancies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.